Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
CAPS Rating:
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
RSS Headlines
Fool UK
Recs
Not a long-termie, because I'm not personally well into the stock and cannot tell whether they have something unique in their safes to take it out by Easter or not.But I can tell a stock with such stats and such current price is to go down.